rofecoxib has been researched along with Diabetes Mellitus, Type 1 in 1 studies
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gysemans, C | 1 |
| Stoffels, K | 1 |
| Giulietti, A | 1 |
| Overbergh, L | 1 |
| Waer, M | 1 |
| Lannoo, M | 1 |
| Feige, U | 1 |
| Mathieu, C | 1 |
1 other study available for rofecoxib and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Prevention of primary non-function of islet xenografts in autoimmune diabetic NOD mice by anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Diabetes Melli | 2003 |